Postprandial C-peptide is more relevant to hemoglobin A1c levels and diabetic microvascular complications than fasting C-peptide in type 2 diabetes

Table 5 Logistic regression of diabetic kidney disease

	Model 1		Model 2		Model 3
	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
FCP	1 (0.999-1.001)	0.805	0.999 (0.998-1)	0.121	0.999 (0.998-1)	0.267
2hCP	1 (1-1)	0.191	1 (0.999-1)	0.082	1 (0.999-1)	0.424
Delta CP	1 (0.999-1)	0.139	1 (0.999-1)	0.137	1 (0.999-1)	0.614
CP ratio	0.998 (0.987-1.009)	0.718	0.999 (0.989-1.009)	0.851	1 (0.99-1.01)	0.957
FCP/fasting plasma glucose	0.997 (0.991-1.003)	0.274	0.993 (0.986-1)	0.052	0.996 (0.988-1.003)	0.239
2hCP/postprandial blood glucose	0.997 (0.994-1)	0.05	0.996 (0.993-1)	0.033	0.998 (0.994-1.002)	0.264
Delta CP/BG	0.995 (0.991-1)	0.045	0.996 (0.991-1.001)	0.09	0.998 (0.993-1.003)	0.444
CP/BG ratio	0.977 (0.872-1.095)	0.687	0.99 (0.948-1.033)	0.635	0.992 (0.958-1.028)	0.67

BG: Blood glucose; CP: C-peptide; FCP: Fasting C-peptide; Model 1: Unadjusted; Model 2: Adjusted for duration, triglyceride, high-density lipoprotein cholesterol, creatinine and uric acid; Model 3: Adjusted for model 2 plus hemoglobin A1c; OR: Odds ratio; 2hCP: 2 hours postprandial C-peptide.